Eli Lilly and Co

The FDA approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, the first drug to directly treat the disorder. The approval is for moderate to severe obstructive sleep apnea in adults with obesity, potentially expanding the market and strengthening Lilly’s case with insurers. Zepbound, a GLP-1 agonist, also reduces food cravings and slows stomach emptying, with trial data showing it eased breathing difficulties and lowered sleep apnea biomarkers.

The FDA approved tirzepatide (Zepbound) for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity, marking the first prescription medicine for OSA. Tirzepatide, used with diet and exercise, showed significant reductions in apnea-hypopnea index (AHI) and body weight in phase III trials. Common side effects include gastrointestinal issues, and it carries a boxed warning about thyroid C-cell tumors.

U.S. FDA approved Eli Lilly's Zepbound, a weight-loss drug, for treating moderate to severe obstructive sleep apnoea (OSA) in obese adults. Zepbound works by reducing appetite and food intake, improving OSA through weight loss. It is administered weekly with exercise and a reduced-calorie diet.

Novo Nordisk's stock dropped over 20% due to disappointing results from a new drug study, affecting Ypsomed's share price. The study showed CagriSema led to 22.7% weight loss, below the expected 25%, despite Novo Nordisk's optimism.

Eli Lilly's Zepbound, a weight-loss drug, was approved by the FDA to treat moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Clinical trials showed Zepbound reduced breathing disruptions five times more than a placebo and led to significant weight loss. This approval may allow Zepbound to be covered by Medicare, similar to Novo Nordisk's Wegovy.

FDA approves Eli Lilly's Zepbound for treating moderate to severe obstructive sleep apnea in obese patients, to be used with a reduced-calorie diet and increased physical activity. Clinical trials showed improved sleep apnea symptoms, and the drug's active ingredient, tirzepatide, is also effective for weight reduction.

Eli Lilly's weight loss drug Zepbound approved by FDA for treating obesity and moderate-to-severe obstructive sleep apnea (OSA), expanding its use and potentially insurance coverage in the U.S. Zepbound, first approved for obesity, is now cleared for OSA, a common sleep-related breathing disorder affecting 80 million in the U.S., with 85% undiagnosed. Eli Lilly expects to launch the drug for OSA early next year, with clinical trials showing Zepbound reduced OSA severity and resolved the condition in nearly half of patients.

The FDA expanded Eli Lilly's Zepbound approval to treat moderate to severe obstructive sleep apnea in obese individuals, the first medication for the condition. Zepbound, aiding weight loss, reduced breathing interruptions and improved sleep apnea symptoms in a study. Insurance providers, including Medicare, may cover it for this dual condition.

FDA approved tirzepatide (Zepbound) for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity, marking the first such prescription medication. Zepbound improves OSA symptoms and aids long-term weight loss, offering a new treatment option for this underdiagnosed condition.

FDA expands Zepbound approval for obstructive sleep apnea in obese adults, making it the first drug treatment for the disorder affecting 39M U.S. adults. Zepbound, sharing active ingredient with Lilly's diabetes drug Mounjaro, aids weight loss, potentially improving symptoms. Current treatments like CPAP machines face issues, prompting interest in drug options. Zepbound showed significant reduction in sleep apnea events in trials, though head-to-head trials against CPAP are needed.